Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

RESCRI	BER	PATIENT:		
lame:		Name:		
Vard:		NHI:		
lening	ococcal B multicomponent vaccine			
Re-asses	ON – Primary immunisation for children up to 12 months of a ssment required after 3 doses sistes (tick boxes where appropriate)	ge		
or	O Three doses for children up to 12 months of age (inclusive O Up to three doses (dependent on age at first dose) for a ca (inclusive) for primary immunisation, from 1 March 2023 to	atch-up programme for children from 13 months to 59 months of age		
	ON – Person is one year of age or over sites (tick boxes where appropriate)			
or or or	Up to two doses and a booster every five years for patients asplenia, HIV, complement deficiency (acquired or inherite  Up to two doses for close contacts of meningococcal case  Up to two doses for person who has previously had mening  Up to two doses for bone marrow transplant patients  Up to two doses for person pre- and post-immunosuppress	s of any group gococcal disease of any group		
Re-asses	ON – Person is aged between 13 and 25 years (inclusive) asment required after 2 doses (sites (tick boxes where appropriate)			
and				
	Immunosuppression due to corticosteroid or other immunosuppr than 28 days.	ressive therapy must be for a period of		

I confirm that the above details are correct:

C:	D-1	
Signed.	Date:	
Oigilica.	 Daic.	